Health & bio

FDA approves Lilly 'Foundayo' (orforglipron) April 1

Once-daily oral GLP-1 for obesity in adults. No meal or time restrictions. Peak dose: 12% weight loss.

Primary sources · 1
CNN
← View the full 2026-04-07 (Tue) issue
What you're reading now arrives in your inbox daily at 21:00 UTC.

Get today's brief every day at 21:00 UTC

7 must-reads · 17 fields · tracked storylines delivered to your inbox daily. Pick only the fields you want; unsubscribe anytime.

Past issues →